GEN Exclusives

More »


More »
May 1, 2009 (Vol. 29, No. 9)

Sugars Are Sweet

  • Glycosylation is one of the most hotly debated phenomena in biotechnology, particularly for development of biosimilars. Regulators are still unsure how glycosylation patterns affect safety and efficacy.

    The research group of Pauline Rudd, Ph.D., a professor at the National Institute for Bioprocessing Research and Training, is developing a database tool that could help.

    GlycoBase, a database of fluorescently labeled glycans and polysaccharide fragments released from monoclonal antibodies and other glycoproteins, answers critical questions on glycosylation patterns and composition, as well as the similarity of glycosylations between two molecules. Because reactor conditions can have profound effects on glycosylation, GlycoBase could also find application in PAT and Quality by Design for processes involving glycosylated biotherapeutics.

    A typical analysis begins with releasing glycans from the protein, labeling them with 2-aminobenzamide, followed by enzymatic digestion. The digest is then analyzed using HILIC (hydrophobic interaction LC), which is ideal for separations based on small differences in polarity. HILIC is also sensitive to polysaccharide structures and linkages, a capability mass detection lacks.

    Finally, the fragments are identified by matching with entries in GlycoBase. The technique is extremely sensitive, as a nanogram of protein is sufficient to perform a full glycan sequence analysis, according to Dr. Rudd.

    Dr. Rudd’s group has collaborated with many academic groups, which have cited GlycoBase extensively in the literature. Companies have also taken notice, among them Eli Lilly, Organon, Schering-Plough, and BD, who have licensed the database for their internal use. 

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »